Search Result

Results for "

NEU2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (4) Influenza Virus (1) Radionuclide-Drug Conjugates (RDCs) (1) Small Interfering RNA (siRNA) (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (8) Infection (1) Inflammation/Immunology (4)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125798

2,3-Dehydro-2-deoxy-N-acetylneuraminic acid 2 Publications Verification NEU5Ac2en; DANA	Influenza Virus	Infection
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) is a potent neuraminidase (sialidase) inhibitor. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid shows inhibitory activities against human neuraminidase enzymes with IC₅₀s of 143, 43, 61, and 74 μM for NEU1, NEU2, NEU3, and NEU4, respectively. Anti-influenza virus activity ^[2].

HY-P1855

*HER2/neu* (654-662) GP2**	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-W087187

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs) EGFR	Cancer
DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.

HY-121605

RL71	Others	Cancer
RL71 is a curcuminoid anticancer agent that exhibits potent cytotoxicity against a variety of ER-negative breast cancer cells. RL71 (1 μM) induces cell cycle arrest in the G2/M phase and induces apoptosis in SKBr3 cells. RL7 also decreases HER2/neu phosphorylation and increases p27. RL71 also significantly reduced the phosphorylation of Akt and transiently increased the stress kinases JNK1/2 and p38 MAPK. Furthermore, RL71 exhibited anti-angiogenic potential in vitro, inhibiting the migration of HUVEC cells and the ability of these cells to form tubular networks .

HY-RS09216

NEU2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NEU2 Human Pre-designed siRNA Set A contains three designed siRNAs for NEU2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NEU2 Human Pre-designed siRNA Set A NEU2 Human Pre-designed siRNA Set A

HY-P10569

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P5745

TYVPANASL	Transmembrane Glycoprotein	Cancer
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	3,045 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 3,045 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

3,045 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,045 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P1855

*HER2/neu* (654-662) GP2**	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers ^[2].

HY-P10569

Biotin HER-2 substrate peptide	EGFR	Cancer
Biotin HER-2 substrate peptide is a substrate of Her4 and Her2/neu tyrosine kinase with a K_m value of 60 μm for Her2/neu kinase domain .

HY-P5745

TYVPANASL	Transmembrane Glycoprotein	Cancer
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5744

SPPHPSPAFSPAFDNLYYWDQ	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743

IRGRILHDGAYSLTLQGLGIH	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH can be used for the research class II HER2-DC1 vaccine studies .

HY-P5745A

TYVPANASL TFA	Peptides	Cancer
TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .

HY-P5744A

SPPHPSPAFSPAFDNLYYWDQ TFA	Peptides	Inflammation/Immunology
SPPHPSPAFSPAFDNLYYWDQ TFA is a multi-epitope class II rat HER2/neu peptide. SPPHPSPAFSPAFDNLYYWDQ TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P5743A

IRGRILHDGAYSLTLQGLGIH TFA	Peptides	Inflammation/Immunology
IRGRILHDGAYSLTLQGLGIH TFA is a multi-epitope class II rat HER2/neu peptide. IRGRILHDGAYSLTLQGLGIH TFA can be used for the research class II HER2-DC1 vaccine studies .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	Peptides	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

Species:	Human (1) Mouse (1)
Tag:	His (3) Myc (1)
Source:	HEK293 (1) Sf9 insect cells (1) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P74733

	NEU2 Protein, Human (HEK293, His) Sialidase-2; Cytosolic sialidase; N-acetyl-alpha-NEUraminidase 2; NEU2	Human	HEK293
	NEU2 protein acts as an exo-α sialidase and selectively hydrolyzes terminal sialic acids in glycolipids, glycoproteins, and oligosaccharides. It shows specificity for α-(2->3)-sialylated GD1a and GT1B gangliosides, preferring α-(2->3) over α-(2->8)-sialylated GD1b. NEU2 Protein, Human (HEK293, His) is the recombinant human-derived NEU2 protein, expressed by HEK293 , with C-His labeled tag. The total length of NEU2 Protein, Human (HEK293, His) is 380 a.a., with molecular weight of ~43.7 kDa.

HY-P72062

	NEU2 Protein, Cricetulus griseus (Baculovirus, His-Myc) NEU2; Sialidase-2; EC 3.2.1.18; Cytosolic sialidase; N-acetyl-alpha-NEUraminidase 2	Others	Sf9 insect cells
	The NEU2 protein plays a key role in cellular processes by catalyzing the removal of sialic acid (N-acetylneuraminic acid) moieties from glycoproteins, oligosaccharides, and gangliosides. Through its enzymatic activity, NEU2 contributes to the controlled modification of cell surface glycoconjugates, affecting various cellular functions including cell adhesion, signaling, and immune responses. NEU2 Protein, Cricetulus griseus (Baculovirus, His-Myc) is the recombinant NEU2 protein, expressed by Sf9 insect cells , with N-10*His, C-Myc labeled tag. The total length of NEU2 Protein, Cricetulus griseus (Baculovirus, His-Myc) is 379 a.a., with molecular weight of ~45.8 kDa.

HY-P702578

	Sialidase-2 Protein, Mouse (P.pastoris, His) NEU2; Sialidase-2; EC 3.2.1.18; Cytosolic sialidase; Mouse skeletal muscle sialidase; MSS; Murine thymic sialidase; MTS; N-acetyl-alpha-NEUraminidase 2	Mouse	P. pastoris

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

NEU2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
NEU2 Human Pre-designed siRNA Set A contains three designed siRNAs for NEU2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.